Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Association of the Cyclooxygenase-2 Gene 8473T>C Polymorphism with Breast Cancer Risk: a Meta-analysis

  • Yang, Xi (Department of Abdominal Cancer, Cancer Center, West China Hospital) ;
  • Zhao, Fen (Department of Oncology, Chengdu First People's Hospital) ;
  • Li, Yue-Hua (Cancer Center, West China Hospital) ;
  • Huang, Min (Department of Pathophysiology, West China School of Preclinical and Forensic Medicine, Sichuan University) ;
  • Huang, Ying (Department of Pathophysiology, West China School of Preclinical and Forensic Medicine, Sichuan University) ;
  • Yi, Cheng (Department of Abdominal Cancer, Cancer Center, West China Hospital)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Associations between the 8473T>C polymorphism (rs5275) in the cyclooxygenase-2 (COX-2) gene and breast cancer (BC) risk are still inconclusive and ambiguous. The aim of this meta-analysis was to comprehensively estimate the genetic risk of 8473T>C polymorphism in the COX-2 gene for BC. Materials and Methods: We searched PubMed, Web of Science, Medline, Chinese biomedical (CBM), Weipu, China national knowledge infrastructure (CNKI), and Wanfang databases, covering all publications (last search was updated on Aug 17, 2014). Statistical analyses were performed using Revman 5.3 and STATA 10.0 software. Results: A total of 6,720 cases and 9,794 controls in 12 studies were included in this study. The results indicated no significant associations between the 8473T>C polymorphism of the COX-2 gene and BC risk for the CC+TC vs TT model (pooled odds ratio (OR)=0.97, 95% confidence interval (CI)=0.90-1.03, and p=0.29). On subgroup analysis, we also found that subdivision on ethnicity among Caucasians, Asians and others also revealed no relationship with BC susceptibility. With the study design (CC+TC vs TT), no significant associations were found in either population-based case-control studies (PCC), or hospital-based case-control studies (HCC). Conclusions: This present meta-analysis suggests that the 8473T>C polymorphism in the COX-2 gene is not a conspicuous low-penetrant risk factor for developing BC.

Keywords

References

  1. Bakhle YS (2001). COX-2 and cancer: a new approach to an old problem. Br J Pharmacol, 134, 1137-50. https://doi.org/10.1038/sj.bjp.0704365
  2. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  3. Brasky TM, Bonner MR, Moysich KB, et al (2011). Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York exposures and breast cancer (WEB) study. Breast Cancer Res Treat, 126, 157-65. https://doi.org/10.1007/s10549-010-1082-x
  4. Cao Y, Prescott SM (2002). Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol, 190, 279-86. https://doi.org/10.1002/jcp.10068
  5. Cox DG, Buring J, Hankinson SE, et al (2007). A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res, 9, 3.
  6. Denkert C, Winzer KJ, Hauptmann S (2004). Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer, 4, 428-33. https://doi.org/10.3816/CBC.2004.n.006
  7. Dong LM, Potter JD, White E, et al (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-36. https://doi.org/10.1001/jama.299.20.2423
  8. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. Fawzy MS, Aly NM, Shalaby SM, et al (2013). Cyclooxygenase-2 169C>G and 8473T>C gene polymorphisms and prostaglandin E2 level in breast cancer: a case-control study. Gene, 527, 601-5. https://doi.org/10.1016/j.gene.2013.06.007
  10. Festa-Vasconcellos JS, Piranda DN, Amaral LM, et al (2012). Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features. Breast Cancer Res Treat, 132, 251-8. https://doi.org/10.1007/s10549-011-1828-0
  11. Gallicchio L, McSorley MA, Newschaffer CJ, et al (2006). Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer, 106, 1443-52. https://doi.org/10.1002/cncr.21763
  12. Gao J, Kang HF, Ma XB, et al (2014). Functional promoter -765 G > C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women. Cancer Cell Int, 14, 38. https://doi.org/10.1186/1475-2867-14-38
  13. Gao J, Ke Q, Ma HX, et al (2007). Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A, 70, 908-15. https://doi.org/10.1080/15287390701289966
  14. Harris RE, Chlebowski RT, Jackson RD, et al (2003). Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res, 63, 6096-101.
  15. He WT, Liu T, Tang XF, et al (2014). The COX-2 -765 G>C polymorphism is associated with increased risk of gastric carcinogenesis in the Chinese Hui ethnic population. Asian Pac J Cancer Prev, 15, 4067-70. https://doi.org/10.7314/APJCP.2014.15.9.4067
  16. Kalalinia F, Elahian F, Hassani M, et al (2012). Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2. Asian Pac J Cancer Prev, 13, 2979-84. https://doi.org/10.7314/APJCP.2012.13.6.2979
  17. Langsenlehner U, Yazdani-Biuki B, Eder T, et al (2006). The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res, 12, 1392-4. https://doi.org/10.1158/1078-0432.CCR-05-2055
  18. Li F, Ren GS, Li HY, et al (2009). A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol, 21, 302-5. https://doi.org/10.1016/j.clon.2008.12.005
  19. Markkula A, Simonsson M, Rosendahl AH, et al (2014). Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients. Int J Cancer, 135, 1898-910. https://doi.org/10.1002/ijc.28831
  20. Pan F, Tian J, Pan Y, et al (2011). Lack of association of the cyclooxygenase 8473 T>C polymorphism with lung cancer: evidence from 9841 subjects. Asian Pac J Cancer Prev, 12, 1941-5.
  21. Peng WJ, Wang BX, He Q, et al (2011). Association of COX-2 8473T>C gene polymorphism with lung cancer risk. Asian Pac J Cancer Prev, 12, 3157-8.
  22. Piranda DN, Festa-Vasconcellos JS, Amaral LM, et al (2010). Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer, 10, 613. https://doi.org/10.1186/1471-2407-10-613
  23. Shah R, Rosso K, Nathanson SD (2014). Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol, 5, 283-98. https://doi.org/10.5306/wjco.v5.i3.283
  24. Shalaby MA, Nounou HA, Ms A, et al (2014). Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population. Asian Pac J Cancer Prev, 15, 4989-94. https://doi.org/10.7314/APJCP.2014.15.12.4989
  25. Shen J, Gammon MD, Terry MB, et al (2006). Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res, 8, 71.
  26. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  27. Simmons DL, Botting RM, Hla T (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev, 56, 387-437. https://doi.org/10.1124/pr.56.3.3
  28. Smith WL, Garavito RM, DeWitt DL (1996). Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem, 271, 33157-60. https://doi.org/10.1074/jbc.271.52.33157
  29. Tabriz HM, Olfati G, Ahmadi SA, et al (2013). Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics. Asian Pac J Cancer Prev, 14, 4539-43. https://doi.org/10.7314/APJCP.2013.14.8.4539
  30. Turk HM, Camci C, Sevinc A, et al (2012). Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Asian Pac J Cancer Prev, 13, 315-8. https://doi.org/10.7314/APJCP.2012.13.1.315
  31. Vogel U, Christensen J, Nexo BA, et al (2007). Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis, 28, 427-34.
  32. Xu YS, Zhao B, Long CY, et al (2014). Cyclooxygenase-2 promoter 765C increase of digestive tract cancer risk in the Chinese population: a meta-analysis. Asian Pac J Cancer Prev, 15, 4563-6. https://doi.org/10.7314/APJCP.2014.15.11.4563
  33. Yu KD, Chen AX, Yang C, et al (2010). Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 122, 251-7. https://doi.org/10.1007/s10549-009-0688-3
  34. Zhang YG, Huang J, Zhang J, et al (2010). RANTES gene polymorphisms and asthma risk: a meta-analysis. Arch Med Res, 41, 50-8. https://doi.org/10.1016/j.arcmed.2010.01.002
  35. Zhao F, Zhu H, Huang M, et al (2014). The 765G>C polymorphism in the cyclooxygenase-2 gene and gastric cancer risk: an update by meta-analysis. Asian Pac J Cancer Prev, 15, 2863-8. https://doi.org/10.7314/APJCP.2014.15.6.2863
  36. Zhu W, Wei BB, Shan X, et al (2010). -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep, 37, 277-88. https://doi.org/10.1007/s11033-009-9685-1